"Designing Growth Strategies is in our DNA"

Cardiac Troponin Market Size, Share & COVID-19 Impact Analysis, By Type (Troponin T and Troponin I), By Setting (Laboratory Testing and Point-of-Care (POC) Testing), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others) By End User (Hospitals & Clinics, Diagnostic Laboratories, and Homecare Settings & Others), and Regional Forecast, 2023-2030

Region : Global | Format: PDF | Report ID: FBI101234

 

KEY MARKET INSIGHTS

Play Audio Listen to Audio Version

The cardiac troponin market size was valued at USD 3.01 billion in 2023 and it is projected to grow USD 5.17 billion by 2030, exhibiting a CAGR of 8.1% during 2023-2030. The rising prevalence of cardiovascular diseases and focus on early diagnosis fuel the market growth.


Cardiac Troponin is considered a primary diagnostic biomarker for detecting cardiac muscle injury.  The accurate and timely diagnosis from this biomarker plays an important role in preventing the risks of adverse effects of heart attack. In recent years, with the advancements in technology and improved knowledge related to cardiac biomarkers, the market has witnessed a significant demand for these products. The early detection of changes in this protein helps in early diagnosis of myocardial infarction (MI).


Troponin I (cTnl) and troponin T (cTnT) are the cardiac regulatory proteins that are involved in controlling calcium-mediated interaction between myosin and actin. These are the biomarkers of myocardial necrosis, and their high cardiac specificity makes them a preferred biomarker for the diagnosis of myocardial infarction.


The growing prevalence of cardiovascular diseases and technological advancements in the products are driving market growth during the forecast period. Additionally, increasing adoption of point-of-care tests in hospital emergency departments is also estimated to drive the cardiac troponin market growth in the future.



  • For instance, as per the data published by Centers for Disease Control and Prevention (CDC) in May 2023, in the U.S. every 40 seconds one individual has a heart attack.


Furthermore, the growing geriatric population is anticipated to increase the demand for treatment and management of acute and chronic health conditions, especially hypertension, heart disease, and stroke.



  • For instance, according to National Center for Health Statistics, the number of Americans aged 65 years and above, increased by roughly 25% from 2003 to 2013 and is expected to increase by another 50% by 2040. Also, from 2018 to 2038, the number of Americans aged 85 years and above is expected to be more than double from 6 million to 14.6 million


COVID-19 IMPACT


Increased Cardiac Troponin Tests Usage in Determining Heart Injury Possibility Propelled Market Growth During Pandemic


The COVID-19 pandemic positively impacted the market growth. The market observed a robust demand for products and services for this protein testing during the pandemic phase. Several studies have demonstrated the association between COVID-19 infection and cardiovascular complications. Individuals infected with SARS-CoV-2 are at high risk of ischemic heart disease, myocarditis, heart failure, pericarditis, dysrhythmia, and thromboembolism. This has resulted in increased demand for troponin tests for the management of cardiovascular diseases (CVD) associated with COVID-19 infection.



  • For instance, according to a research study published in SpringerLink in May 2021, 17% of hospitalized COVID-19 patients in China had elevated levels of this protein.


In 2022, the market experienced a decline in its growth owing to the reduction in the number of these testing procedures.


LATEST TRENDS


Increasing Adoption of Point-of-Care (POC) and High Sensitivity Tests Identified as Significant Market Trends


In recent years, cardiac POC testing has appeared as a favorable tool for diagnosis for reducing cardiovascular disease burden. These tests are being heavily used to gain control on the cardiac diseases. With this, the key players have also introduced point-of-care testing products as well as high-sensitivity tests in the recent years.



  • For instance, in January 2017, the U.S. FDA approved the Elecsys Troponin T Gen 5 STAT test manufactured by Roche. This was the first high-sensitivity troponin test approved in the U.S.


Request a Free sample to learn more about this report.


CARDIAC TROPONIN MARKET GROWTH FACTORS


Growing Prevalence of Cardiovascular Diseases to Drive Demand for Troponin Testing


Rising cases of cardiovascular diseases is one of the main factors for the market growth. The higher levels of this protein are linked to the high risk of heart attack or any cardiac-related indication. With constantly increasing patient population of these diseases, such tests are progressively used to detect myocardial injury.



  • As per the study published by the American College of Cardiology in August 2022, by 2060, the risk factors associated with cardiovascular diseases will increase exponentially, resulting in a steep rise in the patient population for these diseases.


 During the pandemic, doctors recommended this testing to the patients with critical conditions and also to patients under home isolation. Several studies have found that acute myocardial injury is most commonly described in COVID-19 patients.


New Product Launches by Primary Key Market Players to Drive Market Growth


With the increasing usage of troponin testing by end users, the operating players are focusing on the development of new and technologically advanced products to capture the untapped avenues of the market. These developments are expected to boost the market growth in the coming years. The focus of the key players has been increasing to meet the unmet demand of the patient population which is set to drive the market growth during the forecast period.



  • For instance, in June 2018, Beckman Coulter’s new high-sensitivity troponin (hsTnI) product received 510(k) clearance from the U.S. FDA.


RESTRAINING FACTORS


Lack of Sensitivity of Conventional Assays to Limit Product Adoption


Even though troponin is considered as a superior marker for the prediction of cardiovascular diseases as compared to other cardiac biomarkers, there are certain factors that are impeding the market growth. The lack of sensitivity of conventional assays is one of the factors that is restraining the market growth to a certain extent. In addition, these assays also lack in detecting the presence of small amounts of this protein in circulating blood in the first few hours after acute myocardial infarction.


SEGMENTATION


By Type Analysis 


Increasing Number of Troponin I Tests Boosted the Troponin I Segment Growth


By product, the market is categorized into troponin T and troponin I.


The troponin I accounted for the highest global cardiac troponin market share in 2022. This troponin type plays an important role as a specific marker for predicting the risk of cardiovascular disease as well as heart attack. In addition, the development of advanced products, such as point-of-care testing products, has also boosted the segment growth.


On the other hand, the troponin T segment is anticipated to witness significant growth over the projected years. Increasing regulatory approvals for troponin T kits is  propelling the growth of the segment in coming years.


To know how our report can help streamline your business, Speak to Analyst


By Setting Analysis


High Number of Tests Performed at Laboratory Settings Supported the Dominance of the Segment 


Based on setting, the market is segmented into laboratory testing and point-of-care (POC) testing.


The laboratory testing segment held the dominating market share in 2022 and is expected to continue its dominance over the forecast period. The factors driving the segment growth include the fact that the laboratory-based tests provide the detailed analysis compared to point-of-care tests. These tests are a more precise to measure troponin levels. Laboratory testing includes testing in commercial/private health laboratories, public health labs, and hospital-associated laboratories.


The point-of-care (POC) testing segment is set to record the highest market growth rate in the coming years. The factors such as the increasing adoption of these tests in resource-limited settings, introduction of new products, and increasing regulatory approvals for point-of-care testing products are expected to drive the segment growth.


By Indication Analysis


High Prevalence of Acute Coronary Syndrome Augmented Acute Coronary Syndrome Segment Growth


Based on indication, the market is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, and others.


The acute coronary syndrome segment captured the highest global market share in 2022. The rising prevalence of acute coronary syndrome is the major factor that has driven the segment's growth. Cardiac troponin is widely used as a diagnostic biomarker for this disease. The role of this biomarker is well established.



  • For instance, according to an article published in January 2022, an estimated 805,000 American individuals experience an ACS event annually. Out of this, 200,000 are recurrent heart attacks, and 605,000 are new heart attacks.


On the other hand, the myocardial infarction segment accounted for the second-largest market share in 2022. The levels of cardiac troponin are elevated due to myocardial injury. The growing need for the management of this disease is expected to fuel market growth.



  • For instance, according to a study published in NCBI in April 2023, the global prevalence of myocardial infarction in individuals above 60 years was found to be 3.8%. Thus, owing to the increasing rate of MI in the geriatric population, the market is expected to witness significant growth in the coming years.


By End User Analysis


High Rate of Hospital Admissions to Support the Significant Share of Hospitals & Clinics Segment


By end user, the market is categorized into diagnostic laboratories, hospitals & clinics, and homecare settings & others.


The hospitals & clinics segment accounted for the largest market share in 2022. This can be attributed to the growing awareness regarding cardiovascular diseases and the rising adoption of tests by healthcare providers. Furthermore, the SARS-CoV-2 pandemic also supplemented the growth owing to the increased rate of hospitalizations and the usage of these tests in checking the possibility of myocardial infarction in COVID-19 patients.


The diagnostic laboratories segment is estimated to grow considerably over the coming years. Factors influencing the segment growth include the increasing outsourcing activities of the test, particularly in developing countries due to the growing prevalence of cardiovascular disorders.



  • For instance, according to an article published in the National Center for Biotechnology Information (NCBI) in January 2020, the prevalence of coronary artery disease (CAD) in India is 11.0% for nondiabetics and 21.4% for the diabetic population.


REGIONAL INSIGHTS


North America Cardiac Troponin Market Size, 2022 (USD Billion)

To get more information on the regional analysis of this market, Request a Free sample


North America held the largest market share in 2022, generating a revenue of USD 1.14 billion. The region is expected to maintain its domination over the forecast period. Key factors contributing to the market growth include the rising prevalence of cardiovascular diseases in the U.S., increasing product approvals by regulatory bodies, and the availability of advanced products in the region.



  • For instance, in December 2022, Health Canada approved the Quidel TriageTrue High-Sensitivity Troponin I (hsTnl) test for use on the Quidel Triage MeterPro platform. This test provides test results in around 20 minutes.


Additionally, presence of favorable policies for reimbursement and expenditure on healthcare for supporting the cardiovascular diseases in North America are set to drive the region’s market growth. As per the Centers for Disease Control and Prevention (CDC), in the U.S., heart disease costs around USD 219 billion every year. This cost includes the cost of healthcare services, medications, and premature death.


Europe held the second leading market share in the market owing to factors such as new products with CE marks and regulatory framework. The region marks a home to several primary market players such as F. Hoffmann-La Roche Ltd., Eurolyser Diagnostica GmbH, and others.


According to an article published in the National Center for Biotechnology Information (NCBI) in March 2019, high-sensitivity assays for troponin testing have been adopted by around 60% of centers in Europe.


Asia Pacific is anticipated to be the fastest-growing region in the global market. The market is anticipated to register the fastest growth during the study period. This can be attributed to the increasing patient population for cardiovascular diseases in Asian countries and the launch of new products in the region. Additionally, growing focus on  initiatives by the key operating companies for the expansion of their product portfolios and increasing awareness among the people are some other factors supplementing the regional market’s growth.



  • For instance, as per the news article published by The Times of India in April 2023, the hospitals in India have witnessed a spike in these tests in the past years. One of the major hospitals in India, Hiranandani Hospital, Mumbai, has witnessed an increase of 28.6% in the number of troponin tests performed compared to 2021.


Furthermore, the markets in Middle East & Africa, and Latin America regions are estimated to grow at a moderate growth rate over the study period. Key factors contributing to this region’s market growth include the shifting focus of operating entities and government agencies on launching advanced testing facilities and introduction of new products.  


KEY INDUSTRY PLAYERS


F. Hoffmann-La Roche Ltd. to Lead MarketOwing to its Robust Product Portfolio


The market space for cardiac troponin is moderately competitive, with the presence of a substantial number of global as well as domestic market players that are offering troponin testing assays. The COVID-19 pandemic also positively impacted the companies’ revenue growth during the years 2020 and 2021. This is due to the increased demand for this testing in individuals infected with the COVID-19 virus.


F. Hoffmann-La Roche Ltd. is one of the prominent players in the market. The company has a comprehensive portfolio of cardiac troponin. The company has undertaken various strategic initiatives, such as partnerships and collaborations to strengthen its market position. For instance, in April 2021, based on the Elecsys technology, Roche declared a new series of five new intended uses for two key cardiac biomarkers, namely NT-proBNP and cardiac troponin test. This was aimed to expand the company’s market presence by expanding product availability for cardiovascular diagnostics.


Furthermore, other prominent players, such as Abbott, bioMérieux SA, Beckman Coulter, Inc., PerkinElmer Inc., and others, are also adopting several growth strategies, such as mergers & acquisitions, new product launches, and others, which is helping the key market players to contribute to the growing competition and also expand their customer base by implementing various strategies.


LIST OF KEY COMPANIES PROFILED IN CARDIAC TROPONIN MARKET:



KEY INDUSTRY DEVELOPMENTS



  • April 2023 - Bio-Rad Laboratories launched a four-level multi-analyte cardiac quality control for high-sensitivity troponin testing. This product is expected to enhance the sensitivity of the diagnostic assays for the detection of cardiac biomarkers.

  • February 2023 - Pathology Queensland (PQ) announced that it has installed a new highly sensitive cardiac troponin (hs-cTnI) assay in all Queensland Hospital laboratories during 2022.

  • October 2022 - HyTest Ltd launched five new antibodies specific for cTnI. These products can be used for quantitative cTnI immunoassay development.

  • December 2019 – Mayo Clinic switched to Roche Diagnostics’ Elecsys Troponin T Gen 5 Stat assay. This was the first high-sensitivity cardiac troponin test with the U.S. FDA approval.


REPORT COVERAGE


An Infographic Representation of Cardiac Troponin Market

To get information on various segments, share your queries with us



The global market report provides an in-depth analysis of the industry. It focuses on market segments, such as type, setting, indication, and end-user. Besides this, it offers the global cardiac troponin market forecast in relation to the current market dynamics, the impact of COVID-19, and latest market trends. Additionally, the report consists of several factors that have contributed to the market’s growth. The report also provides the competitive landscape of the market.


Report Scope & Segmentation






















































ATTRIBUTE



DETAILS



Study Period



2019-2030



Base Year



2022



Estimated Year  



2023



Forecast Period



2023-2030



Historical Period



2019-2021



Growth Rate



CAGR of 8.1% from 2023-2030



Unit



Value (USD Billion)



Segmentation



By Type



  • Troponin T

  • Troponin I



By Setting



  • Laboratory Testing

  • Point-of-Care (POC) Testing



By Indication



  • Myocardial Infarction

  • Congestive Heart Failure

  • Acute Coronary Syndrome

  • Others



By End User



  • Hospitals & Clinics

  • Diagnostic Laboratories

  • Homecare Settings & Others



By Region



  • North America ( By  Type, By Setting, By Indication, By End User, By Country)


    • U.S.

    • Canada


  • Europe ( By  Type, By Setting, By Indication, By End User, By Country/Sub-Region)


    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Rest of Europe


  • Asia Pacific (  By  Type, By Setting, By Indication, By End User, By Country/Sub-Region)


    • China

    • Japan

    • India

    • Australia

    • Rest of Asia Pacific


  • Latin America (  By  Type, By Setting, By Indication, By End User, By Country/Sub-Region)


    • Brazil

    • Mexico

    • Rest of Latin America


  • Middle East & Africa (By  Type, By Setting, By Indication, By End User, By Country/Sub-Region)


    • GCC

    • South Africa

    • Rest of Middle East & Africa




 


Frequently Asked Questions

Fortune Business Insights says that the global market stood at USD 2.79 billion in 2022 and is projected to reach USD 5.17 billion by 2030.

In 2022, the market value stood at USD 1.14 billion.

The market will exhibit a steady CAGR of 8.1% during the forecast period of 2023-2030.

Currently, the laboratory testing segment will be leading the market by setting.

The rising prevalence of cardiovascular diseases, increasing research & development activities by major market players, rising number of approvals, and launch of innovative POC products are the key drivers of the market.

Abbott, F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, Quest Diagnostics Incorporated, and PerkinElmer Inc. are the major players in the market.

North America dominated the market in 2022.

The surge in the demand for effective treatment of cardiovascular diseases, increased adoption of technologically advanced diagnostic testing, and a considerable patient population base are some of the factors expected to drive the adoption of these products.

Seeking Comprehensive Intelligence on Different Markets?
Get in Touch with Our Experts

Speak to an Expert
  • Oct, 2023
  • 2022
  • 2019-2021
  • 150

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $6850

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Client Testimonials

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X